Jiten Patel, MD
Pulmonary Disease · Spokane, WANPI 1689895211
Payments from drug & device makers
Across 697 payments — averaging $567.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$204K
- Actelion Pharmaceuticals US, Inc.$58K
- Concordia Laboratories Inc.$38K
- Bayer$34K
- United Therapeutics Corporation$27K
- Actelion Pharmaceuticals, Ltd$19K
- plus $17K from 32 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 143 | $203,636 |
| Actelion Pharmaceuticals US, Inc. | 81 | $58,163 |
| Concordia Laboratories Inc. | 10 | $37,882 |
| Bayer | 11 | $34,253 |
| United Therapeutics Corporation | 53 | $26,691 |
| Actelion Pharmaceuticals, Ltd | 12 | $18,701 |
| Intuitive Surgical | 22 | $6,392 |
| AstraZeneca | 72 | $1,807 |
| GSK | 145 | $1,482 |
| Steris Corporation | 5 | $1,438 |
| Pulmonx Corporation | 5 | $1,313 |
| Electromed, Inc. | 19 | $694 |
| Grifols USA, LLC | 9 | $325 |
| Boston Scientific | 4 | $272 |
| Regeneron Healthcare Solutions, Inc. | 9 | $258 |
| Insmed, Inc. | 6 | $250 |
| Sanofi | 11 | $243 |
| Merck | 7 | $197 |
| Sanofi-aventis U.S. LLC | 3 | $186 |
| Mylan Specialty L.p. | 10 | $183 |
| Baxter Healthcare | 7 | $175 |
| Genentech USA, Inc. | 9 | $173 |
| Galvanize Therapeutics, Inc | 1 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $134 |
| Philips North America LLC | 7 | $126 |
| Amgen | 6 | $124 |
| Johnson & Johnson | 1 | $122 |
| Advanced Respiratory, Inc | 6 | $116 |
| Verona Pharma, Inc. | 4 | $87 |
| Pinnacle Biologics, Inc | 4 | $85 |
| Pfizer | 1 | $62 |
| Gilead | 2 | $41 |
| Novartis | 1 | $33 |
| Sunovion Pharmaceuticals Inc. | 2 | $27 |
| Covidien LP | 1 | $18 |
| Viatris Specialty LLC | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Medtronic | 1 | $12 |
How this compares
$395,882 in reported general payments places this provider in the 95th percentile of 275 pulmonary disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Spokane
- Allison LambertSpokane$352K
- Jonathan DanarajSpokane$142K
- Bryan AndersonSpokane$56K
- Griffith LiangSpokane$13K
- Fatima AjazSpokane$6K
- Benjamin ArthursSpokane$6K
- Harshwant GroverSpokane$6K
- Peter ChenSeattle$2.7M
- Tomasz ZiedalskiEverett$1.6M
- William ParkRenton$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.